Cardiometabolic
AstraZeneca’s Wainua lowered a disease-causing protein but did not reduce heart complications in a major trial
AstraZeneca and Ionis’ eplontersen achieved its intended biological effect in transthyretin amyloid cardiomyopathy, substantially suppressing circulating TTR, yet failed to significantly reduce cardiovascular death and recurrent cardiovascular events in the overall CARDIO-TTRansform population.
The same weight loss produced different metabolic benefits. Diet quality may matter as much as kilograms lost
Do patients need maximum-dose tirzepatide forever? New data suggest a middle ground
Sprint interval training triggered a bigger molecular response than 90 minutes of cycling. Bigger is not yet better
One in four Korean adults met MASLD criteria. Four everyday habits were linked to 29% lower odds
More spice did not improve post-meal metabolism. A four-week trial complicates the heart-health story
Gut bacteria could help explain how vegetable-rich diets protect cardiometabolic health
Coffee drinkers had less visceral fat despite similar BMI. The finding exposes what the scale misses
Avexitide Phase 3 trial cuts post-bariatric hypoglycemia events by 55%
A sweat patch can continuously track cholesterol and triglycerides. Blood tests are not obsolete yet
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.